JuHyun Bae | Cancer immunotherapy | Best Researcher Award

Best Researcher Award

JuHyun Bae
Affiliation Kyungpook National University School of Medicine
Country South Korea
Scopus ID 57225046295
Documents 15
Citations 375
h-index 10
Subject Area Cancer Immunotherapy
Event Biotechnology Scientist Awards
ORCID 0000-0002-2025-3772

JuHyun Bae
Kyungpook National University School of Medicine

JuHyun Bae, a researcher affiliated with Kyungpook National University School of Medicine, South Korea. This publication-style profile summarizes publicly available scholarly information, including research metrics, publication output, citation performance, scientific contributions, and subject expertise in Cancer Immunotherapy. The article follows a neutral, Wikipedia-inspired presentation suitable for academic recognition and professional reference.[1]

Abstract

JuHyun Bae has established a research profile focused on Cancer Immunotherapy through peer-reviewed scientific publications indexed in international bibliographic databases. Current publicly available metrics indicate 15 indexed publications, 375 citations, and an h-index of 10, reflecting consistent scientific productivity and measurable scholarly influence. This article summarizes the research profile using an objective academic format appropriate for institutional review and research recognition.[1]

Keywords

Cancer Immunotherapy, Oncology, Immunology, Precision Medicine, Translational Medicine, Biomedical Research, Scientific Publications, Citation Analysis, Biotechnology Scientist Awards, Best Researcher Award.

Introduction

Academic excellence is evaluated through a combination of research quality, publication output, citation performance, innovation, and contributions to scientific advancement. Bibliometric databases such as Scopus provide standardized indicators that assist universities, research organizations, funding agencies, and award committees in conducting objective evaluations while complementing expert peer review.[2]

Research Profile

JuHyun Bae is affiliated with Kyungpook National University School of Medicine in South Korea. The available scholarly record demonstrates active research in Cancer Immunotherapy with publications appearing in internationally indexed journals. The research portfolio contributes to ongoing investigations in biomedical science, translational medicine, and cancer-related therapeutic strategies.[1]

Research Contributions

  • Published peer-reviewed research in Cancer Immunotherapy and biomedical sciences.
  • Supported advances in translational oncology research.
  • Contributed to internationally indexed scientific literature.
  • Participated in collaborative biomedical research activities.
  • Enhanced scientific knowledge through evidence-based medical research.

Publications

The researcher’s Scopus profile records 15 indexed publications. These scholarly works contribute to Cancer Immunotherapy and related biomedical disciplines. Many scientific articles include Digital Object Identifiers (DOIs), providing permanent identification and reliable access to published research while supporting accurate scholarly citation.[3]

  • Peer-reviewed journal publications indexed in Scopus.
  • Research articles in oncology, immunology, and translational medicine.

Research Impact

Bibliometric indicators report 15 indexed documents, 375 citations, and an h-index of 10. These metrics demonstrate measurable scholarly visibility and research influence within the biomedical sciences. Quantitative indicators should be interpreted together with publication quality, originality, scientific rigor, collaborative engagement, and broader contributions to medical research.[1]

Award Suitability

Based on publicly available academic indicators, JuHyun Bae demonstrates characteristics commonly considered during evaluations for recognition programs such as the Biotechnology Scientist Awards. Consideration may include publication quality, research significance, citation influence, innovation, ethical research conduct, collaborative achievements, and contributions to Cancer Immunotherapy. Final award decisions remain subject to independent peer review and committee evaluation.[2]

Conclusion

This academic profile presents a structured overview of JuHyun Bae’s scholarly achievements using publicly available bibliographic information. The article follows a neutral encyclopedia-style presentation that emphasizes research productivity, publication performance, scientific impact, and professional contributions, making it suitable for academic reference, institutional evaluation, and research recognition.[1]

References

  1. Elsevier. (n.d.). Scopus Author Details: JuHyun Bae, Author ID 57225046295. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57225046295
  2. Systematic discovery of immunomodulatory plant-derived nanoparticles reveals RNA-mediated macrophage reprogramming.
    https://www.sciencedirect.com/science/article/pii/S2452199X26003701?via%3Dihub
  3. Determination of extracellular vesicle size and surface charge density via precise measurements of Brownian motion, electrophoretic velocity, and applied electric field in a single platform.
    https://www.sciencedirect.com/science/article/abs/pii/S0925400526001486?via%3Dihub

Assist. Prof. Dr. Keyang Xu | oncology | Best Researcher Award

Assist. Prof. Dr. Keyang Xu | oncology | Best Researcher Award

Assist. Prof. Dr. Keyang Xu | Macau University of Science and Technology | China

πŸŽ“ Dr. Keyang Xu is an Assistant Professor at the Faculty of Chinese Medicine, Macau University of Science and Technology. His research explores the intersections of oncology and metabolism, focusing on exosomes, proteomics, noncoding RNA, and natural therapies. With extensive experience from prestigious institutions like Hong Kong Baptist University and the University of Sydney, Dr. Xu is dedicated to advancing cancer research and translational medicine. He actively contributes as an editor for Frontiers in Oncology and the Journal of Taibah University for Science, driving scientific innovation in his field.

Professional Profile:

ORCID

Suitability for Best Researcher Award

Dr. Keyang Xu is an exceptional candidate for the Best Researcher Award, given his pioneering contributions to oncology and metabolism. As an Assistant Professor at the Faculty of Chinese Medicine, Macau University of Science and Technology, Dr. Xu explores cutting-edge areas including exosomes, proteomics, noncoding RNA, and natural therapies, which are at the forefront of cancer research and translational medicine. His interdisciplinary approach bridges traditional Chinese medicine with modern biomedical science, paving the way for innovative cancer therapies.

Education & Experience:

  • πŸŽ“ Ph.D. in Chinese Medicine – Hong Kong Baptist University (2021-2024)
  • πŸŽ“ Visitor Scholar – Storr Liver Center, University of Sydney (2024)
  • πŸŽ“ Master’s Degree – Chinese & Western Clinical Medicine, Zhejiang Chinese Medical University (2016-2019)
  • πŸŽ“ Medicine Degree – Chengdu University of Traditional Chinese Medicine (2011-2016)
  • πŸ§‘β€πŸ« Assistant Professor – Macau University of Science and Technology (2025-Present)
  • πŸ”¬ Research Assistant – Hong Kong Baptist University (2020-2024)
  • 🩺 Physician – Lvkang Geriatric Rehabilitation Hospital, Hangzhou (2019-2020)
  • 🩺 Physician – Xiwenbeiyuan Clinic, Hangzhou (2018-2019)

Professional Development:

🌏 Global Collaborations – Dr. Xu has collaborated internationally, including with renowned experts at the Storr Liver Center in Sydney.
πŸ“š Editorial Roles – He actively contributes to scientific literature as an editor for Frontiers in Oncology and the Journal of Taibah University for Science.
πŸŽ“ Mentorship & Teaching – As an Assistant Professor, he guides future researchers and medical professionals.
πŸ”¬ Innovative Research – His research delves into the roles of exosomes, proteomics, noncoding RNA, and natural therapies in oncology and metabolism.
🀝 Professional Memberships – Active in the Good Practice in Traditional Chinese Medicine Research Association and Student Networks on EVs, fostering a collaborative scientific community.

Research Focus:

🧬 Oncology & Metabolism – Investigating the mechanisms linking cancer and metabolic disorders.
πŸ“¦ Exosomes – Exploring the role of adipose tissue-derived exosomes in cancer metastasis and metabolic regulation.
πŸ§ͺ Proteomics – Utilizing omics approaches to understand protein profiles influenced by obesity and metabolic changes.
🧬 Noncoding RNA – Investigating lncRNAs’ role in cancer progression and recurrence, particularly in HBV-related hepatocellular carcinoma.
🌿 Natural Therapy – Examining the therapeutic effects of natural compounds like Resveratrol on metabolic diseases and cancer.

Awards & Honors:

  • πŸ… Research Grant – High-fat diet-enhanced colorectal cancer metastasis project (RC-FNRA-IG/20-21/SCM/01)
  • πŸ… Research Grant – Effects of obesity on exosomal protein profiles (#2021Szvup131)
  • πŸ… Research Grant – Molecular mechanism of LncBRM in HBV-related hepatocellular carcinoma (LSY19H030002)
  • πŸ… Research Grant – Treating hyperuricemia-related NAFLD with Resveratrol (2014ZA090)
  • πŸ… Research Grant – Clinical value of CHI3L1 in chronic hepatitis B (2019KY532)

Publication Top Notes:

  • “An Integration of RNA Sequencing and Network Pharmacology Approaches Predicts the Molecular Mechanisms of the Huo-Xue-Shen Formula in the Treatment of Liver Fibrosis”Β  – πŸ§¬πŸ“Š
  • “Exosomes in Skin Flap Survival: Unlocking Their Role in Angiogenesis and Tissue Regeneration”Β  – 🧫🩺
  • “Shared Genetic Links Between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease” – 🧬❀️
  • “Exploring Tumor Heterogeneity in Colorectal Liver Metastases by Imaging: Unsupervised Machine Learning of Preoperative CT Radiomics Features for Prognostic Stratification”Β  – πŸ§ πŸ€–
  • “Elevated Extracellular Matrix Protein 1 in Circulating Extracellular Vesicles Supports Breast Cancer Progression Under Obesity Conditions” – πŸ§¬βš–οΈ
  • “Untimely Surgery for Stent-Fracture-Related Death After Transjugular Intrahepatic Portosystemic Shunt: A Case Report” – πŸ©ΊπŸ“„
  • “Brevilin A is a Potent Anti-Metastatic CRC Agent That Targets the VEGF-IL6-STAT3 Axis in the HSCs-CRC Interplay”Β  – πŸ§¬πŸ›‘οΈ